Sumitomo Mitsui Trust Group Inc. Acquires 1,319,464 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

Sumitomo Mitsui Trust Group Inc. increased its holdings in Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 60.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,510,518 shares of the company's stock after purchasing an additional 1,319,464 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 4.82% of Schrödinger worth $67,718,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SDGR. Harbor Capital Advisors Inc. boosted its position in Schrödinger by 5.0% during the third quarter. Harbor Capital Advisors Inc. now owns 13,059 shares of the company's stock worth $242,000 after purchasing an additional 622 shares during the period. KBC Group NV boosted its holdings in shares of Schrödinger by 45.4% during the 3rd quarter. KBC Group NV now owns 2,508 shares of the company's stock worth $47,000 after buying an additional 783 shares during the period. Redwood Wealth Management Group LLC boosted its holdings in shares of Schrödinger by 8.4% during the 4th quarter. Redwood Wealth Management Group LLC now owns 14,620 shares of the company's stock worth $283,000 after buying an additional 1,132 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company's stock worth $54,000 after buying an additional 1,305 shares during the period. Finally, Private Advisor Group LLC boosted its holdings in shares of Schrödinger by 20.5% during the 3rd quarter. Private Advisor Group LLC now owns 12,150 shares of the company's stock worth $225,000 after buying an additional 2,065 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Schrödinger Trading Up 2.4 %

Shares of Schrödinger stock traded up $0.57 during trading on Thursday, reaching $24.43. The company's stock had a trading volume of 692,406 shares, compared to its average volume of 914,351. Schrödinger, Inc. has a one year low of $16.67 and a one year high of $33.63. The stock has a 50-day moving average price of $21.81 and a two-hundred day moving average price of $20.36. The stock has a market capitalization of $1.78 billion, a P/E ratio of -10.44 and a beta of 1.61.

Schrödinger (NASDAQ:SDGR - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.12). The business had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger's revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.86) earnings per share. As a group, sell-side analysts anticipate that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SDGR. BMO Capital Markets increased their target price on Schrödinger from $25.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. KeyCorp increased their price objective on Schrödinger from $25.00 to $27.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.11.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.